Eli Lilly and Company
Eli Lilly Announces Strong Q4 2025 Results and 2026 Guidance
Summary
Eli Lilly and Company reported a 43% increase in Q4 2025 revenue to $19.3 billion, driven by volume growth from Mounjaro and Zepbound. The company posted a 51% increase in reported EPS to $7.39 and a 42% increase in non-GAAP EPS to $7.54, inclusive of $0.52 of acquired IPR&D charges. Regulatory approvals for Kwikpen and Jaypirca were achieved, and submissions for new treatments were made. The company also announced an agreement with the U.S. government to expand access to obesity medicines. 2026 guidance anticipates revenue between $80 billion and $83 billion and non-GAAP EPS between $33.50 and $35.00.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement